MA54615A - Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation - Google Patents

Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation

Info

Publication number
MA54615A
MA54615A MA054615A MA54615A MA54615A MA 54615 A MA54615 A MA 54615A MA 054615 A MA054615 A MA 054615A MA 54615 A MA54615 A MA 54615A MA 54615 A MA54615 A MA 54615A
Authority
MA
Morocco
Prior art keywords
monoclonal antibody
antibody against
against human
human interleukin
alpha receptor
Prior art date
Application number
MA054615A
Other languages
English (en)
Inventor
Wei Chen
Huaiyao Qiao
Jiwan Qiu
Zhihua Qiu
Yiliang Wu
Original Assignee
Qyuns Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qyuns Therapeutics Co Ltd filed Critical Qyuns Therapeutics Co Ltd
Publication of MA54615A publication Critical patent/MA54615A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054615A 2018-12-25 2019-12-25 Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation MA54615A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811592427.XA CN110746507B (zh) 2018-12-25 2018-12-25 抗人白介素4受体α单克隆抗体及其应用

Publications (1)

Publication Number Publication Date
MA54615A true MA54615A (fr) 2021-11-03

Family

ID=69275667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054615A MA54615A (fr) 2018-12-25 2019-12-25 Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation

Country Status (8)

Country Link
US (1) US20220073631A1 (fr)
EP (1) EP3902837A4 (fr)
JP (1) JP7118480B2 (fr)
CN (5) CN111494625B (fr)
AU (1) AU2019416486B2 (fr)
CA (1) CA3124726A1 (fr)
MA (1) MA54615A (fr)
WO (1) WO2020135471A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
CN114605539B (zh) * 2020-12-09 2024-01-02 南京融捷康生物科技有限公司 人源化的抗IL-4Rα单域抗体及其应用
EP4019546A1 (fr) * 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
EP4019090A1 (fr) * 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
EP4267615A1 (fr) * 2020-12-23 2023-11-01 Numab Therapeutics AG Domaines variables d'anticorps se liant à il-4r
EP4019547A1 (fr) * 2020-12-23 2022-06-29 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour il-4r et il-31
TW202328183A (zh) 2021-08-05 2023-07-16 美商美國禮來大藥廠 人類介白素-4受體α抗體
US20240024472A1 (en) 2022-05-02 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations
US20240199688A1 (en) 2022-05-02 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
CN115960236A (zh) * 2023-01-05 2023-04-14 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (fr) * 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2001272925A1 (en) 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
BRPI0710572A2 (pt) 2006-01-24 2013-01-08 Domantis Ltd ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) * 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US20100008914A1 (en) 2006-12-15 2010-01-14 Murray Lynne A Methods and compositions for treating il-4 and il-13 related fibrosis related pathologies
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
EP3211010A1 (fr) 2007-12-21 2017-08-30 Medimmune Limited Éléments de liaison pour le récepteur alpha interleukin-4 (il-4r) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009114828A1 (fr) 2008-03-13 2009-09-17 Childrens Hospital Medical Center Compositions et procédés relatifs à des états d’allergie gastro-intestinale
JP6161233B2 (ja) 2008-03-31 2017-07-12 ジェネンテック， インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
US20110008326A1 (en) * 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
WO2010054667A1 (fr) * 2008-11-17 2010-05-20 Københavns Universitet Peptides dérivés d’il-4 pour la modulation de la réponse inflammatoire chronique et le traitement de maladies auto-immunes
TR201901826T4 (tr) * 2011-12-13 2019-03-21 Astrazeneca Ab Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler.
WO2013087912A1 (fr) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Composés et méthodes de traitement de maladies inflammatoires
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
KR102576903B1 (ko) * 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
SG10201913822PA (en) * 2012-09-07 2020-03-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20150139905A (ko) 2013-04-05 2015-12-14 제넨테크, 인크. 항-il-4 항체 및 이중특이적 항체 및 그의 용도
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN105517570B (zh) 2013-06-21 2020-04-07 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
MX2016010854A (es) 2014-02-21 2017-01-05 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
ES2973858T3 (es) 2014-02-28 2024-06-24 Regeneron Pharma Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
US20170281769A1 (en) * 2014-09-03 2017-10-05 Medimmune Limited STABLE ANTI-IL-4Ra FORMULATION
CN107206073A (zh) 2014-11-14 2017-09-26 赛诺菲生物技术公司 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CA3035202A1 (fr) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methodes de prevention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR20190053250A (ko) * 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
CN108640991B (zh) * 2018-05-17 2019-09-27 江苏荃信生物医药有限公司 抗人白介素17a单克隆抗体及其应用
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物

Also Published As

Publication number Publication date
CN111494625A (zh) 2020-08-07
CN110746507B (zh) 2020-06-26
WO2020135471A1 (fr) 2020-07-02
US20220073631A1 (en) 2022-03-10
CN111494626A (zh) 2020-08-07
AU2019416486B2 (en) 2022-07-07
JP7118480B2 (ja) 2022-08-16
EP3902837A1 (fr) 2021-11-03
JP2022516483A (ja) 2022-02-28
CN111494626B (zh) 2022-06-21
CN111494625B (zh) 2022-06-21
AU2019416486A1 (en) 2021-07-08
CN111518211A (zh) 2020-08-11
CN111514292B (zh) 2023-06-20
CN110746507A (zh) 2020-02-04
CN111518211B (zh) 2022-06-21
CN111514292A (zh) 2020-08-11
CA3124726A1 (fr) 2020-07-02
EP3902837A4 (fr) 2022-06-15

Similar Documents

Publication Publication Date Title
MA54615A (fr) Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation
MA52091A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
IL284216B (en) Anti-transferrin receptor antibodies and their uses
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3878868A4 (fr) Anticorps humain présentant une affinité élevée vis-à-vis du récepteur alpha d'il -4 humain, et son utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
MA50534A (fr) Variant d'anticorps et isoforme à activité biologique réduite
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
MA55615A (fr) Anticorps humains qui se lient au ret et leurs procédés d'utilisation
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
EP4169948A4 (fr) Anticorps anti-cd73 et son utilisation
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
IL287690A (en) Antibodies against hvem and their use
MA52165A (fr) Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof